BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27145458)

  • 1. Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.
    Meltzer S; Kalanxhi E; Hektoen HH; Dueland S; Flatmark K; Redalen KR; Ree AH
    Oncotarget; 2016 Jun; 7(23):34907-17. PubMed ID: 27145458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The short-term outcomes of induction SOX (S-1 + oxaliplatin) ± cetuximab chemotherapy followed by short-course chemoradiotherapy in patients with poor-risk locally advanced rectal cancer.
    Beppu N; Yoshie H; Kimura F; Aihara T; Doi H; Kamikonya N; Matsubara N; Tomita N; Yanagi H; Yamanaka N
    Surg Today; 2016 Oct; 46(10):1123-31. PubMed ID: 26704191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
    Gao YH; An X; Sun WJ; Cai J; Cai MY; Kong LH; Lin JZ; Liu GC; Tang JH; Wu XJ; Chen G; Pan ZZ; Ding PR
    J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
    Flatmark K; Saelen MG; Hole KH; Abrahamsen TW; Fleten KG; Hektoen HH; Redalen KR; Seierstad T; Dueland S; Ree AH
    Radiother Oncol; 2016 Jun; 119(3):505-11. PubMed ID: 26968754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer.
    Ng SY; Colborn KL; Cambridge L; Cercek A; Reidy-Lagunes DL; Segal N; Stadler Z; Saltz LB; Paty PB; Guillem J; Weiser MR; Nash G; Garcia-Aguilar J; Goodman KA
    Clin Colorectal Cancer; 2019 Sep; 18(3):167-174. PubMed ID: 31104990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative chemoradiotherapy with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer: long-term results of a phase II trial.
    Liu L; Cao C; Zhu Y; Li D; Feng H; Luo J; Tang Z; Liu P; Lu K; Ju H; Zhang N
    Med Oncol; 2015 Mar; 32(3):70. PubMed ID: 25694046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
    Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
    Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.
    Kalanxhi E; Hektoen HH; Meltzer S; Dueland S; Flatmark K; Ree AH
    BMC Cancer; 2016 Jul; 16():536. PubMed ID: 27461255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
    J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
    Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
    Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer.
    De Felice F; Benevento I; Magnante AL; Musio D; Bulzonetti N; Caiazzo R; Tombolini V
    BMC Cancer; 2017 May; 17(1):325. PubMed ID: 28499428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pelvic MRI after induction chemotherapy and before long-course chemoradiation therapy for rectal cancer: What are the imaging findings?
    Gollub MJ; Blazic I; Bates DDB; Campbell N; Knezevic A; Gonen M; Lynn P; Weiser MR; Garcia-Aguilar J; Hötker AM; Cercek A; Saltz L
    Eur Radiol; 2019 Apr; 29(4):1733-1742. PubMed ID: 30280248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
    Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
    Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
    Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer.
    Barsukov YA; Gordeyev SS; Tkachev SI; Fedyanin MY; Perevoshikov AG
    Colorectal Dis; 2013 Sep; 15(9):1107-14. PubMed ID: 23668626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy.
    Huang XZ; Gao P; Song YX; Sun JX; Chen XW; Zhao JH; Ma B; Wang J; Wang ZN
    Oncotarget; 2016 Apr; 7(15):19643-53. PubMed ID: 26910371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.
    Kalanxhi E; Meltzer S; Schou JV; Larsen FO; Dueland S; Flatmark K; Jensen BV; Hole KH; Seierstad T; Redalen KR; Nielsen DL; Ree AH
    Br J Cancer; 2018 May; 118(10):1322-1328. PubMed ID: 29695770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.